Icatibant (30 mg)
SHP-FIR-101
Phase 1 small_molecule completed
Quick answer
Icatibant (30 mg) for Hereditary Angioedema (HAE) is a Phase 1 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Hereditary Angioedema (HAE)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed